GTX Corp's Phase III Clinical Studies of Enobosarm (GTx-024) to Continue as Planned Following Planned Safety Review
4/15/2013 12:17:42 PM
More...
|
GTx, Inc. (GTXI)-758 Poster Presentation of Phase II Trial Data in Advanced Prostate Cancer Selected as One of the Best Posters at the 28th Annual European Association of Urology Congress
3/19/2013 9:41:32 AM
More...
|
GTX Corp Release: Aetrex Navistar™ GPS SHOES for Tracking Alzheimer's Sufferers Now Available in the UK and Ireland
10/11/2012 11:28:37 AM
More...
|
GTX Corp to Present Scientific Poster Presentations on Enobosarm to Prevent and Treat Muscle Wasting in Cancer Patients
10/8/2012 9:50:20 AM
More...
|
GTX Corp Announces Presentation on the Ability of Capesaris® to Reduce Free Testosterone and Suppress PSA in Men With Castration Resistant Prostate Cancer
9/19/2012 8:49:19 AM
More...
|
GTX Corp Announces Symposium and Presentation of Data on Muscle Wasting in Non-Small Cell Lung Cancer Patients
9/17/2012 9:25:00 AM
More...
|
GTX Corp Announces Webcast of Corporate Presentation at NewsMakers in the Biotech Industry Conference
8/28/2012 9:46:20 AM
More...
|
GTX Corp Announces Webcast of Corporate Presentation at Stifel Nicolaus 2012 Healthcare Conference
8/27/2012 9:45:25 AM
More...
|
GTX Corp Announces Webcast of Corporate Presentation at Wedbush 2012 Life Sciences: Management Access Conference
8/6/2012 9:27:58 AM
More...
|
GTX Corp Submits Clinical Hold Complete Response Letter to FDA For Its Planned Phase II Clinical Study Of Capesaris® For Secondary Hormonal Therapy of Advanced Prostate Cancer
4/4/2012 6:59:50 AM
More...
|
|